Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

Are we ready for therapeutic drug monitoring of biologic therapeutics?

Charlotte LM Krieckaert1* and Willem F Lems12

Author Affiliations

1 Jan van Breemen Research Institute/Reade, dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands

2 Department of Rheumatology, VU University Medical Centre, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13:120  doi:10.1186/ar3395


See related research by Ducourau et al., http://arthritis-research.com/content/13/3/R105

Published: 2 August 2011

Abstract

In the previous issue of Arthritis Research & Therapy, Ducourau and colleagues report that they retrospectively detected anti-infliximab antibodies in 21% of patients with rheumatic diseases. Patients with anti-infliximab antibodies had lower serum drug concentrations. These findings contribute to the existing evidence of immunogenicity of biologicals and its clinical relevance. We argue for therapeutic drug monitoring to optimize treatment response.